Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$2.24B |
| 2 |
Apple
AAPL
|
+$1.14B |
| 3 |
Tesla
TSLA
|
+$1.05B |
| 4 |
Shopify
SHOP
|
+$1B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$901M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$1.13B |
| 2 |
Netflix
NFLX
|
+$1.1B |
| 3 |
NVO
Novo Nordisk
NVO
|
+$1.03B |
| 4 |
Eli Lilly
LLY
|
+$931M |
| 5 |
Trade Desk
TTD
|
+$899M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 40.77% |
| 2 | Communication Services | 17.54% |
| 3 | Consumer Discretionary | 14.14% |
| 4 | Healthcare | 7% |
| 5 | Financials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Sprout Social
SPT
$527M
| $21.3M | 0.01% |
1,645,017
-747,433
| -31% | -$12.2M |
|
327
Antero Midstream
AM
$10.2B
| $21M | 0.01% |
1,082,266
| – | – |
|
328
Vertex
VERX
$1.93B
| $20.3M | 0.01% |
819,128
+294,421
| +56% | +$8.53M |
|
329
Cabaletta Bio
CABA
$448M
| $19.9M | 0.01% |
8,497,537
+2,477,370
| +41% | +$4.25M |
|
330
Corning
GLW
$138B
| $19.7M | 0.01% |
239,889
-551,986
| -70% | -$36.1M |
|
331
Adaptive Biotechnologies
ADPT
$3.93B
| $19.6M | 0.01% |
1,311,487
+1,215,715
| +1,269% | +$14.8M |
|
332
Agilysys
AGYS
$3.13B
| $19.3M | 0.01% |
+183,784
| New | +$20.3M |
|
333
Oneok
OKE
$54.2B
| $19.1M | 0.01% |
262,331
| – | – |
|
334
Corteva
CTVA
$53.4B
| $19M | 0.01% |
281,349
-7,532
| -3% | -$546K |
|
335
PENN Entertainment
PENN
$2.69B
| $18.2M | 0.01% |
945,360
-6,194
| -0.7% | -$116K |
|
336
Twist Bioscience
TWST
$6.87B
| $17.9M | 0.01% |
634,600
+16,350
| +3% | +$495K |
|
337
Apollo Global Management
APO
$76.2B
| $17.5M | 0.01% |
131,022
-278,994
| -68% | -$39.5M |
|
338
Tandem Diabetes Care
TNDM
$1.33B
| $17.2M | 0.01% |
1,420,116
-238,826
| -14% | -$3.23M |
|
|
EXAS
339
DELISTED
Exact Sciences
EXAS
| $16.8M | 0.01% |
306,196
-199,069
| -39% | -$9.95M |
|
340
Baker Hughes
BKR
$61.3B
| $16.5M | 0.01% |
+337,843
| New | +$14.9M |
|
341
Gilead Sciences
GILD
$164B
| $16.4M | 0.01% |
148,143
-499,194
| -77% | -$56.7M |
|
342
Illumina
ILMN
$30.3B
| $15.9M | 0.01% |
167,847
-32,360
| -16% | -$3.21M |
|
343
Prestige Consumer Healthcare
PBH
$2.48B
| $15.7M | 0.01% |
252,216
-15,727
| -6% | -$1.09M |
|
344
Western Midstream Partners
WES
$19B
| $15.5M | 0.01% |
395,716
-189,988
| -32% | -$7.42M |
|
345
American Tower
AMT
$76.5B
| $15.5M | 0.01% |
80,442
-3,359
| -4% | -$700K |
|
|
SEI
346
Solaris Energy Infrastructure
SEI
$3.59B
| $15.4M | 0.01% |
386,447
+373,854
| +2,969% | +$11.7M |
|
347
Casey's General Stores
CASY
$31.9B
| $15.4M | 0.01% |
27,297
-1,878
| -6% | -$982K |
|
348
Hess Midstream
HESM
$5.13B
| $15.3M | 0.01% |
441,729
-154,903
| -26% | -$6.14M |
|
|
CWAN
349
DELISTED
Clearwater Analytics
CWAN
| $14.9M | 0.01% |
828,878
+794,617
| +2,319% | +$16.1M |
|
350
Valero Energy
VLO
$88.5B
| $14.9M | 0.01% |
87,339
+24,400
| +39% | +$3.64M |
|
Similar funds
Jennison Associates's Q3 2025 Portfolio in Review
As of Q3 2025, Jennison Associates held 667 positions worth $172B, up 1.9% from $169B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Jennison Associates withdrew a net $8.14B in Q3 2025, closing 107 positions and reducing 253 holdings. Its most notable exit was Fair Isaac, an estimated $172M position sold in full.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 36% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, Jennison Associates opened a new position in Advanced Micro Devices worth $627M.
- Jennison Associates's largest Q3 2025 buy was Advanced Micro Devices: 3,874,319 shares worth $627M.
- Jennison Associates added most to Oracle in Q3 2025, an estimated $2.24B increase.
- Jennison Associates's biggest Q3 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $1.13B.
- Jennison Associates fully exited Fair Isaac in Q3 2025, selling an estimated $172M.
- Jennison Associates's ten largest holdings make up 47% of its $172B portfolio in Q3 2025.
- Jennison Associates opened 93 new positions and closed 107 in Q3 2025.
- Jennison Associates's portfolio value rose 1.9% quarter-over-quarter to $172B.
Based on Jennison Associates's 13F filing for Q3 2025, filed 30 Oct 2025.